|
|
|
| Effect of Trimebutin Maleate and Stomach Granules Combined with Mosapride on Functional Dyspepsia and Its Effects on Serum 5-HT NO SP and Gastrointestinal Hormone |
| LI Wen, DING Yuanyuan, LIU Chenchen, et al |
| The First People's Hospital of Jining City, Shandong Jining 272000, China |
|
|
|
|
Abstract Objective: To discuss the therapeutic effect of trimebutin maleate and stomach granules combined with mosapride on functional dyspepsia and its effects on serum 5-hydroxytryptamine (5-HT), nitric oxide (NO) and substance P (SP) and gastrointestinal hormone. Methods: 82 patients with functional dyspepsia admitted to our hospital from March 2015 to March 2016 were selected and divided into control group and research group according to simple random method, 41 in each. The control group was given medication treatment of mosapride, and the research group was additionally given trimebutin maleate on the basis of control group.Then the clinical curative effect, changes of symptom score, the serum levels of 5-HT, NO and SP, motilin (MTL), gastrin (GAS), gastric antrum movement index (MI), amplitude (ΔA/A), the contraction frequency (F), gastric half emptying time (T1/2) before and after the treatment, and incidence of adverse reactions were compared between both groups. Results: The total effective rate of research group was higher than that of the control group (P<0.05); After treatment, the levels of serum 5-HT, NO, T1/2 in both groups decreased, and the levels of serum SP, MTL, GAS, MI, ΔA/A, F in both groups increased. Moreover, the differences between the above indexes in the research group before and after treatment were significantly higher than those in the control group, and the differences were statistically significant (P<0.05). Conclusion: The therapeutic effect of trimebutin maleate combined with mosaprib in the treatment of functional dyspepsia is superior to that of mosaprib alone, which may be related to the effective regulation of serum 5-ht, NO and SP levels in patients and the improvement of gastrointestinal hormones
|
|
|
|
|
|
[1] 丁顺斌,蔡明春,张文利,等.双歧杆菌三联活菌联合莫沙必利对功能性消化不良患者的疗效及对血液流变学和血清胃肠激素水平的影响[J].海南医学院学报,2016,22(21):2548~2550.
[2] 李文刚,周立君,吴冬寒,等.莫沙必利对功能性消化不良及近端胃舒张和胃排空功能的疗效研究[J].重庆医学,2015,44(2):148~150.
[3] 于惠玲,鲁素彩,孟杰,等.马来酸曲美布汀联合舒肝颗粒治疗功能性消化不良的临床疗效及安全性评价[J].中国临床药理学杂志,2016,32(6):499~501.
[4] 黄欣,王萍.莫沙必利联合马来酸曲美布汀治疗功能性消化不良的疗效观察[J].临床消化病杂志,2017,29(2):65~68.
[5] 张蓉,卢王,张哲,王景杰.马来酸曲美布汀联合疏肝解郁胶囊治疗功能性消化不良的疗效观察[J].广西医科大学学报,2017,34(11):1632~1635.
[6] 常颖,于惠玲,鲁素彩,等.舒肝颗粒联合马来酸曲美布汀治疗功能性消化不良不同亚型的临床疗效[J].河北医药,2016,38(23):3586~3587.
[7] 俞媛洁,陈继红.5－羟色胺与胃肠动力障碍的关系[J].医学综述,2016,22(4):636~639.
[8] 郭华,张靖,田静,等.莫沙必利联合奥美拉唑对老年功能性消化不良患者胃肠激素与胃肠动力的影响[J].国际消化病杂志,2018,38(2):121~125. |
|
|
|
2020, Vol. 26 
